Goldman Sachs analyst Matthew Sykes initiated coverage of Iqvia with a Buy rating and $270 price target. The analyst initiated coverage of the contract research organizations sector, believing the industry represents an undervalued approach to gain exposure to a potential recovery in large pharma and emerging biotech spend. The firm sees Iqvia as a well diversified business well positioned for share gains with a market leading position in data and technology.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IQV:
- Here’s what Wall Street experts are saying about Salesforce ahead of earnings
- IQVIA Holdings Announces Executive Team Reshuffle and Role Change
- Iqvia price target lowered to $245 from $254 at Baird
- Iqvia backs FY24 adjusted EPS view $10.95-$11.25, consensus $11.11
- Iqvia reports Q1 EPS $2.54, consensus $2.48